TechnoVax is a privately held near-clinical-stage biotechnology company specializing in viral vaccine development. The defined mission is to create and develop unique and novel vaccine technologies with no current alternatives. TechnoVax has developed a next-generation technology platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. This technology offers the ability to keep-up with constantly changing infectious treats.The industry and the scientific community strongly believe that VLP based vaccines are the technology of the future! The company plans to approach the clinical phases with 3 main vaccines candidates: (1) Universal or Broadly Neutralizing Influenza Vaccine (2) Non-Refrigerated, Inhaled Powder or Reconstituted, Influenza Vaccine and (3) VLP-based Respiratory Syncytial Virus (RSV) Vaccine. TechnoVax has partnered with a leading player in the field of pulmonary drug delivery to develop shelf-stable, self- inhaled powder VLP vaccines for flu and RSV for which no such product is currently available.respir
